References
- 1. Nestle FO, Kaplan DH, Barker J. Psoriasis. New Eng J Med. 2009;361(5):496-509.
- 2. Christiophers E, Henseter T. Psoriasis type I and type II as subtypes of non pustular psoriasis. In: Roenigk H, Maibach H, editors. Psoriasis. New York: Dekker; 1990. p. 15-21.
- 3. Vasků V, Bienertová Vasků J, Pávková Goldbergová M, Vasků A. Three retinoid x receptor gene polymorphism in plaque psoriasis and psoriasis guttata. Dermatology. 2007;214(2):118-24.
- 4. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-50.
- 5. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58(5):851-64.10.1016/j.jaad.2008.02.04018423261
- 6. Boker A, Kimball AB, Rolz-Cruz G. Biologicals in the treatment of psoriasis. Curr Opin Investig Drugs. 2007;8(11):939-46.
- 7. Barlett BL, Tyring SK. Ustekinumab for chronic plaque psoriasis. Lancet. 2008;371(9625):1639-40.
- 8. Torti DC, Feldman SR. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol. 2007;57(6):1059-68.
- 9. Reddy M, Davis C, Wong J, Marsters P, Pendley C, Prabhakar U. Modulation of CLA, IL-12R, CD40L, and IL-2pα expression and inhibition of IL-12 and IL-23 induced cytokine secretion by CNTO1275. Cell Immunol. 2007;247(1):1-11.
- 10. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-wk result from a randomised, double-blind, placebo-controlled trial (PHOENIX1). Lancet. 2008;371(9625):1665-74.
- 11. Steinman L. A brief history of Th17, the first major revision in Th1/Th2 hypothesis of T cell-mediated tissue damage. Nat Med. 2007;13(2):139-45.10.1038/nm1551
- 12. Asarch A, Barak O, Loo DS, Gottlieb AB. Th17 cells: a new therapeutic target in inflammatory dermatosis. J Dermatolog Treat. 2008;19(6):318-26.
- 13. Lebwohl M. Psoriasis. Lancet. 2003;361(9364):1197-204.
- 14. Naldi L, Gambini D. The clinical spectrum of psoriasis. Clin Dermatol. 2007;25(6):510-8.
- 15. Menter A, Griffiths CE. Current and future management of psoriasis. Lancet. 2007;370(9583):272-84.
- 16. Griffiths CE, Iaccarino L, Naldi L, Olivieri I, Pipitone N, Salvarani C, et al. Psoriasis and psoriatic arthritis: immunological aspects and therapeutic guidelines. Clin Exp Rheumatol. 2006;24 (1 Suppl 40);72-8.
- 17. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody in patient with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX2). Lancet 2008;371(9625):1675-84.
- 18. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-50. SAME AS REF 3
- 19. Ellis CN, Krueger GG; Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effecter T lymphocytes. N Engl J Med. 2001;345(4):248-55.
- 20. Papp KA, Carey W. Psoriasis care. New and emerging pharmacologic trends. J Cutan Med Surg. 2010;14 (3):119-29.10.2310/7750.2010.09039
- 21. Weger W. Current status and new development in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol. 2010;160(4):810-20.
- 22. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody. Nat Rev Drug Discov. 2010;9(10):767-74.10.1038/nrd3229